Compare Heron Therapeutics Inc (HRTX) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Invesco NASDAQ 100 ETF — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Invesco NASDAQ 100 ETF trades at $290.26. The key difference: Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | QQQM | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.96 | $307.23 |
52-Week Low | $0.39 | $228.02 |
Enterprise Value | $189.36M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
QQQM trades at $286.58 with minimal daily movement (+0.09%), reflecting a bearish technical signal amid neutral oscillators. The ETF's lower 0.15% expense ratio compared to QQQ attracts long-term growth investors, while recent Nasdaq-100 inclusion of SpaceX (1% weighting) adds diversification. Support levels cluster near $285-$283, with resistance at $288-$292.
Outlook remains tied to tech sector performance, with AI infrastructure spending by holdings like Amazon ($200B annual CapEx guidance) as a key catalyst. Risks include stretched valuations and rising AI competition. The bearish technical bias suggests near-term consolidation, but the fund's cost efficiency supports long-term growth exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
